Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.

Oncotarget - 12 Jul 2016

Ai Bo, Liu Huiquan, Huang Yu, Peng Ping

Abstract excerpt

Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this issue, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell-Free Nucleic Acids
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Outcome Assessment, Health Care

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 27323821
DOI: 10.18632/oncotarget.10069
PMCID: PMC5190120

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.PMID 27323821Read ↗

Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patientsSemantic proximity Read ↗

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line ChemotherapySemantic proximity Read ↗

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.Semantic proximity Read ↗

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancerSemantic proximity Read ↗

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.Semantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.Semantic proximity Read ↗

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.